Header Logo

Connection

RAMMURTI KAMBLE to Adult

Back to Details
This is a "connection" page, showing publications RAMMURTI KAMBLE has written about Adult.
RAMMURTI KAMBLE
Connection Strength
0.930
Adult
  1. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
    View in: PubMed
    Score: 0.039
  2. Voriconazole photosensitivity causes apparent graft-versus-host disease exacerbation. Bone Marrow Transplant. 2019 02; 54(2):323-325.
    View in: PubMed
    Score: 0.036
  3. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.026
  4. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.017
  5. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.016
  6. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplant. 2007 Jan; 39(1):49-52.
    View in: PubMed
    Score: 0.016
  7. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1201-2.
    View in: PubMed
    Score: 0.016
  8. Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease. Bone Marrow Transplant. 2006 Jun; 37(11):1065-6.
    View in: PubMed
    Score: 0.015
  9. Leukemia burden and outcome of allogeneic transplant in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2006 Jun; 12(6):691-2.
    View in: PubMed
    Score: 0.015
  10. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):506-10.
    View in: PubMed
    Score: 0.015
  11. Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. Biol Blood Marrow Transplant. 2006 Jan; 12(1):111-2.
    View in: PubMed
    Score: 0.015
  12. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma. 2005 Aug; 46(8):1137-42.
    View in: PubMed
    Score: 0.015
  13. Re: failure to engraft after autologous stem cell transplantation: possible therapeutic role of cyclosporine. Biol Blood Marrow Transplant. 2005 Jan; 11(1):74.
    View in: PubMed
    Score: 0.014
  14. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.014
  15. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
    View in: PubMed
    Score: 0.012
  16. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.012
  17. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.012
  18. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.011
  19. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021 08 01; 106(8):2295-2296.
    View in: PubMed
    Score: 0.011
  20. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.011
  21. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.011
  22. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452.
    View in: PubMed
    Score: 0.010
  23. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer. 2021 02 15; 127(4):609-618.
    View in: PubMed
    Score: 0.010
  24. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190.
    View in: PubMed
    Score: 0.010
  25. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biol Blood Marrow Transplant. 2020 09; 26(9):1747-1756.
    View in: PubMed
    Score: 0.010
  26. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020 08; 26(8):1459-1468.
    View in: PubMed
    Score: 0.010
  27. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
    View in: PubMed
    Score: 0.010
  28. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020 06; 26(6):1210-1217.
    View in: PubMed
    Score: 0.010
  29. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
    View in: PubMed
    Score: 0.010
  30. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2020 03; 26(3):553-561.
    View in: PubMed
    Score: 0.010
  31. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020 03; 26(3):472-479.
    View in: PubMed
    Score: 0.010
  32. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019 10 22; 3(20):3123-3131.
    View in: PubMed
    Score: 0.010
  33. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.010
  34. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019 10; 19(10):2900-2909.
    View in: PubMed
    Score: 0.010
  35. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
    View in: PubMed
    Score: 0.010
  36. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1875-1883.
    View in: PubMed
    Score: 0.009
  37. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019 02 26; 3(4):670-680.
    View in: PubMed
    Score: 0.009
  38. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 06; 25(6):1099-1106.
    View in: PubMed
    Score: 0.009
  39. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biol Blood Marrow Transplant. 2019 07; 25(7):1325-1330.
    View in: PubMed
    Score: 0.009
  40. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04; 25(4):683-688.
    View in: PubMed
    Score: 0.009
  41. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant. 2019 02; 25(2):270-278.
    View in: PubMed
    Score: 0.009
  42. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
    View in: PubMed
    Score: 0.009
  43. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 12; 24(12):2443-2449.
    View in: PubMed
    Score: 0.009
  44. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv. 2018 05 08; 2(9):1022-1031.
    View in: PubMed
    Score: 0.009
  45. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):932-937.
    View in: PubMed
    Score: 0.009
  46. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 06; 24(6):1163-1171.
    View in: PubMed
    Score: 0.009
  47. Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. J Obstet Gynaecol Res. 1997 Jun; 23(3):261-6.
    View in: PubMed
    Score: 0.008
  48. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2017 Aug; 23(8):1320-1326.
    View in: PubMed
    Score: 0.008
  49. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966.
    View in: PubMed
    Score: 0.008
  50. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):971-979.
    View in: PubMed
    Score: 0.008
  51. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017 05 15; 123(10):1828-1838.
    View in: PubMed
    Score: 0.008
  52. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb; 23(2):269-277.
    View in: PubMed
    Score: 0.008
  53. Allogeneic Transplantation for Relapsed Waldenstr?m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 01; 23(1):60-66.
    View in: PubMed
    Score: 0.008
  54. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014.
    View in: PubMed
    Score: 0.008
  55. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.008
  56. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016 06 01; 34(16):1864-71.
    View in: PubMed
    Score: 0.008
  57. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 07; 174(2):235-48.
    View in: PubMed
    Score: 0.008
  58. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant. 2016 06; 22(6):1056-1064.
    View in: PubMed
    Score: 0.008
  59. Cutaneous metastases of lung cancer. Postgrad Med J. 1995 Dec; 71(842):741-3.
    View in: PubMed
    Score: 0.007
  60. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biol Blood Marrow Transplant. 2016 Mar; 22(3):520-7.
    View in: PubMed
    Score: 0.007
  61. Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.
    View in: PubMed
    Score: 0.007
  62. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016 Jan; 51(1):58-66.
    View in: PubMed
    Score: 0.007
  63. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10; 33(32):3741-9.
    View in: PubMed
    Score: 0.007
  64. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Feb; 22(2):248-257.
    View in: PubMed
    Score: 0.007
  65. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec; 50(12):1513-8.
    View in: PubMed
    Score: 0.007
  66. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Nov; 50(11):1416-23.
    View in: PubMed
    Score: 0.007
  67. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1830-8.
    View in: PubMed
    Score: 0.007
  68. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplant. 2015 Aug; 50(8):1057-62.
    View in: PubMed
    Score: 0.007
  69. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8.
    View in: PubMed
    Score: 0.007
  70. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplant. 2015 Feb; 50(2):197-203.
    View in: PubMed
    Score: 0.007
  71. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):151-8.
    View in: PubMed
    Score: 0.007
  72. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71.
    View in: PubMed
    Score: 0.007
  73. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1777-84.
    View in: PubMed
    Score: 0.007
  74. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1729-36.
    View in: PubMed
    Score: 0.007
  75. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8.
    View in: PubMed
    Score: 0.007
  76. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014 Mar; 20(3):402-408.e1.
    View in: PubMed
    Score: 0.007
  77. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4.
    View in: PubMed
    Score: 0.007
  78. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
    View in: PubMed
    Score: 0.006
  79. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.006
  80. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.006
  81. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.006
  82. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013 Aug; 48(8):1091-7.
    View in: PubMed
    Score: 0.006
  83. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May; 19(5):746-53.
    View in: PubMed
    Score: 0.006
  84. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Apr; 19(4):625-31.
    View in: PubMed
    Score: 0.006
  85. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
    View in: PubMed
    Score: 0.006
  86. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013 Mar; 48(3):363-8.
    View in: PubMed
    Score: 0.006
  87. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1776-84.
    View in: PubMed
    Score: 0.006
  88. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
    View in: PubMed
    Score: 0.006
  89. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012 Jun; 47(6):831-7.
    View in: PubMed
    Score: 0.006
  90. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18; 118(7):1979-88.
    View in: PubMed
    Score: 0.005
  91. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 Aug 10; 28(23):3730-8.
    View in: PubMed
    Score: 0.005
  92. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
    View in: PubMed
    Score: 0.005
  93. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010 Mar; 16(3):395-402.
    View in: PubMed
    Score: 0.005
  94. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.
    View in: PubMed
    Score: 0.005
  95. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006 Aug; 28(4):254-8.
    View in: PubMed
    Score: 0.004
  96. Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis. J Mol Diagn. 2006 May; 8(2):288-94.
    View in: PubMed
    Score: 0.004
  97. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet. 2006 Mar; 165(2):176-9.
    View in: PubMed
    Score: 0.004
  98. Spinal ganglioneuroblastoma--complete response to chemotherapy alone. Postgrad Med J. 1993 Sep; 69(815):746-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.